文献速递新发突发、热带与寄生虫病

在非洲HIV感染与非HIV成人中加速异源两剂埃博拉疫苗方案的安全性与免疫原性

Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
PubMed 文献 · Clin Infect Dis · 2024-01-01

这项在5个撒哈拉以南非洲国家开展的随机、观察者盲、安慰剂对照2期试验纳入无HIV人群(n=249)和HIV感染者(n=250),评估两种加速埃博拉疫苗方案。结果显示两种方案均安全,未出现疫苗相关严重不良事件,第2剂后21天结合抗体应答率分别为99%(14天方案)和98%(28天方案)。

要点

  • 两种加速方案(14天间隔和28天间隔)在无HIV人群和HIV感染者中均安全,未报告疫苗相关严重不良事件。
  • 第2剂后21天,14天方案结合抗体应答率为99%,28天方案为98%。
  • 第2剂后12个月,无HIV人群和HIV感染者的几何平均浓度在两种方案中均有所下降。

核心结论

  • 加速14天和28天埃博拉疫苗方案在非洲无HIV人群和HIV感染者中安全且具有免疫原性。

研究设计与样本

  • 随机、观察者盲、安慰剂对照2期试验,在5个撒哈拉以南非洲国家开展。
  • 纳入无HIV人群(n=249)和HIV感染者(n=250),成人参与者接受14天间隔MVA-BN-Filo、Ad26.ZEBOV方案(n=79)、28天间隔Ad26.ZEBOV、MVA-BN-Filo方案(n=322)或生理盐水/安慰剂(n=98)。

主要发现

  • 平均年龄33.4岁,52%为女性;HIV感染者中位CD4+细胞计数为560.0 cells/μL(四分位距418.0-752.0)。
  • 不良事件总体为轻/中度,无疫苗相关严重不良事件,安全性特征按HIV状态无显著差异。
  • 第2剂后21天,14天方案疫苗接受者EBOV糖蛋白特异性结合抗体应答率为99%(几何平均浓度:无HIV人群5168 EU/mL;HIV感染者2509 EU/mL)。
  • 第2剂后21天,28天方案疫苗接受者应答率为98%(几何平均浓度:无HIV人群6037 EU/mL;HIV感染者2939 EU/mL)。
  • 第2剂后12个月,14天方案无HIV人群和HIV感染者几何平均浓度分别为635和514 EU/mL;28天方案分别为331和360 EU/mL。

关键数值与推荐

  • 结合抗体应答者定义为较基线升高>2.5倍或基线阴性时达到定量下限的参与者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shorter prophylactic vaccine schedules may offer more rapid protection against Ebola in resource-limited settings. METHODS: This randomized, observer-blind, placebo-controlled, phase 2 trial conducted in 5 sub-Saharan African countries included people without human immunodeficiency virus (HIV) (PWOH, n = 249) and people with HIV (PWH, n = 250). Adult participants received 1 of 2 accelerated Ebola vaccine regimens (MVA-BN-Filo, Ad26.ZEBOV administered 14 days apart [n = 79] or Ad26.ZEBOV, MVA-BN-Filo administered 28 days apart [n = 322]) or saline/placebo (n = 98). The primary endpoints were safety (adverse events [AEs]) and immunogenicity (Ebola virus [EBOV] glycoprotein-specific binding antibody responses). Binding antibody responders were defined as participants with a >2.5-fold increase from baseline or the lower limit of quantification if negative at baseline. RESULTS: The mean age was 33.4 years, 52% of participants were female, and among PWH, the median CD4+ cell count was 560.0 (interquartile range, 418.0-752.0) cells/μL. AEs were generally mild/moderate with no vaccine-related serious AEs or remarkable safety profile differences by HIV status. At 21 days post-dose 2, EBOV glycoprotein-specific binding antibody response rates in vaccine recipients were 99% for the 14-day regimen (geometric mean concentrations [GMCs]: 5168 enzyme-linked immunosorbent assay units [EU]/mL in PWOH; 2509 EU/mL in PWH) and 98% for the 28-day regimen (GMCs: 6037 EU/mL in PWOH; 2939 EU/mL in PWH). At 12 months post-dose 2, GMCs in PWOH and PWH were 635 and 514 EU/mL, respectively, for the 14-day regimen and 331 and 360 EU/mL, respectively, for the 28-day regimen. CONCLUSIONS: Accelerated 14- and 28-day Ebola vaccine regimens were safe and immunogenic in PWOH and PWH in Africa. Clinical Trials Registration. NCT02598388.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mwesigwa B, Sawe F, Oyieko J, et al. Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa. Clin Infect Dis. 2024. PMID: 38657084. doi:10.1093/cid/ciae215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。